Progenics to Advance Oral Methylnaltrexone into Late Stage Clinical Development

Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010.

Read full story

Share

No related posts.

Leave a Reply

Spam Protection by WP-SpamFree



Subscribe without commenting


Advertisement
Donate to Us

Have we helped or inspired YOU today?

Subscribe by RSS
Subscribe by Email:
Delivered by FeedBurner
February 2012
MTWTFSS
« Jan  
 12345
6789101112
13141516171819
20212223242526
272829 


Page 1 of 11

Page optimized by WP Minify WordPress Plugin